The Future of Anticoagulation

Click to increase image sizeClick to decrease image size

Disclaimer

The opinions expressed in this interview are those of the interviewees and do not necessarily reflect the views of Future Medicine Ltd.

Financial & competing interests disclosure

The study referenced in this article was funded by Daiichi Sankyo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The study referenced in this article was funded by Daiichi Sankyo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Notes on contributors

Catherine Lichten

Joanna Chataway & Catherine Lichten speak to Ellen Clark, Commissioning Editor:Joanna Chataway is a Director of the Innovation, Health and Science Group at RAND Europe. She has held senior positions and appointments across a range of academic, policy research, consulting and research funding bodies. She has >25 years of experience in the areas of research, innovation and technology policy. She has particular expertise in the fields of global development and health innovation and has researched extensively the range of factors that influence the rate and direction of product and process innovation in health. Her research has spanned public and private sectors and she has worked in industrially developed and developing countries. She has researched and reported on regulation, standards, public opinion, finance, institutional and organizational arrangements, public/private partnerships, intellectual property and clinician and patient behaviors in relation to medical and health innovation. In addition to her RAND appointment, Chataway is a professor at The Open University and is currently a senior leader of the Innogen Institute (formerly the ESRC Innogen Centre), which conducts a broad range of interdisciplinary research projects on social and economic aspects of innovation in life sciences. Innogen is based at The Open University and The University of Edinburgh. Chataway received her PhD from The Open University. She is a member of the Phi Beta Kappa Honors Society.

Catherine Lichten is a researcher in the Innovation, Health and Science Group at RAND Europe. Her research interests focus on strategies for supporting research and innovation, particularly in health. Her recent work includes an assessment of the UK’s dementia research landscape and opportunities for capacity–building, and an international mapping of the mental health research funding landscape. Prior to joining RAND, she worked as a journalist covering life sciences research policy in the UK and the Europe. She holds a PhD in computational biology from McGill University in Canada.